Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
Apply
64Cu-DOTA-Pembrolizumab
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step